Overview


According to FutureWise analysis the market for kirsten rat sarcoma (KRAS) in 2023 is US$ 98.13 million, and is expected to reach US$ 138.70 million by 2031 at a CAGR of 4.42%.

The kirsten rat sarcoma (KRAS) market is being buoyed by an increasing trend in in vitro diagnostics and ongoing research in the treatment section. As the number of people diagnosed with lung cancer has increased, so has the demand for Kirsten rat sarcoma (KRAS). Because of innovative pharmaceutical development and the production of new medications to combat various tumours, the kirsten rat sarcoma (KRAS) market is expanding. Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven pancreatic cancer is extremely lethal, with only a 9% five-year survival rate. Because of the unique characteristics of pancreatic tumours, several treatment techniques, including chemotherapy, radiation, and immunotherapy, demonstrated only moderate efficacy. Surgery is the primary curative option in the early stages of the disease, but it is only used in 20% of people with early stage disease.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Kirsten Rat Sarcoma (KRAS) Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Kirsten Rat Sarcoma (KRAS) Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • F. Hoffmann-La Roche Ltd
  • Qiagen
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott
  • NimaGen BV
  • Agena Bioscience Inc.
  • BML Inc.
  • Takara Bio Inc.
  • New England Biolabs
  • Amoy Diagnostics Co Ltd
  • Panagene
  • EntroGen
  • Sysmex Corporation
  • Biocartis

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Breast Cancer
  • Pancreatic Cancer
  • Colon Cancer
  • Lung Cancer
  • Others

By Application

  • Development and Drug Formulation
  • Development of Molecular Diagnostics
  • Disease Diagnostics
  • Drug Discovery and Development
  • Personalised Medicine
  • Predictive
  • Prognostics
  • Research and Development
  • Risk Assessment
  • Therapeutic

By End-use

  • Academic and Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Cancer Diagonostic Centers and Research Laboratories
  • Clinic Laboratories
  • Contract Research Organizations (CRO)
  • Healthcare IT/Big Data Companies
  • Hospitals
  • Pharma and Biotech Companies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Kirsten Rat Sarcoma (KRAS) Market By Type, By Application, By End-use and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Kirsten Rat Sarcoma (KRAS) Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Kirsten Rat Sarcoma (KRAS) Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Kirsten Rat Sarcoma (KRAS) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Kirsten Rat Sarcoma (KRAS) Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Breast Cancer
        2. Pancreatic Cancer
        3. Colon Cancer
        4. Lung Cancer
        5. Others

  • 8.   Kirsten Rat Sarcoma (KRAS) Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Development and Drug Formulation
        2. Development of Molecular Diagnostics
        3. Disease Diagnostics
        4. Drug Discovery and Development
        5. Personalised Medicine
        6. Predictive
        7. Prognostics
        8. Research and Development
        9. Risk Assessment
        10. Therapeutic

  • 9.   Kirsten Rat Sarcoma (KRAS) Market, By End-use Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Academic and Cancer Research Institutes
        2. Ambulatory Surgical Centers
        3. Cancer Diagonostic Centers and Research Laboratories
        4. Clinic Laboratories
        5. Contract Research Organizations (CRO)
        6. Healthcare IT/Big Data Companies
        7. Hospitals
        8. Pharma and Biotech Companies

  • 10.   North America Kirsten Rat Sarcoma (KRAS) Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.   Latin America Kirsten Rat Sarcoma (KRAS) Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.   Europe Kirsten Rat Sarcoma (KRAS) Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.   Asia Pacific Kirsten Rat Sarcoma (KRAS) Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts)

    •   1. F. Hoffmann-La Roche Ltd
         1.1. Company Overview
         1.2. Type Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Qiagen
         2.1. Company Overview
         2.2. Type Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Agilent Technologies Inc.
         3.1. Company Overview
         3.2. Type Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Illumina Inc.
         4.1. Company Overview
         4.2. Type Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Thermo Fisher Scientific Inc.
         5.1. Company Overview
         5.2. Type Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Abbott
         6.1. Company Overview
         6.2. Type Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. NimaGen BV
         7.1. Company Overview
         7.2. Type Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Agena Bioscience Inc.
         8.1. Company Overview
         8.2. Type Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. BML Inc.
         9.1. Company Overview
         9.2. Type Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Takara Bio Inc.
         10.1. Company Overview
         10.2. Type Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. New England Biolabs
          11.1. Company Overview
          11.2. Type Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Amoy Diagnostics Co Ltd
          12.1. Company Overview
          12.2. Type Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Panagene
          13.1. Company Overview
          13.2. Type Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. EntroGen
          14.1. Company Overview
          14.2. Type Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Sysmex Corporation
          15.1. Company Overview
          15.2. Type Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
          16. Biocartis
          16.1. Company Overview
          16.2. Type Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11